Pyridone-containing farnesyltransferase inhibitors: Synthesis and biological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 4001-4005

  Hasvold, Lisa A ^a   Wang, Weibo ^a   Gwaltney II, Stephen L ^a   Rockway, Todd W ^a   Nelson, Lissa T J ^a   Mantei, Robert A ^a   Fakhoury, Stephen A ^a   Sullivan, Gerard M ^a   Li, Qun ^a   Lin, Nan Horng ^a   Wang, Le ^a   Zhang, Haiying ^a   Cohen, Jerome ^a   Gu, Wen Zhen ^a   Marsh, Kennan ^a   Bauch, Joy ^a   Rosenberg, Saul ^a   Sham, Hing L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 315493; ABT 839; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG EFFECT; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

MURINAE;

EID: 10744220773     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.08.058     Document Type: Article

References (9)

1. Prendergast G.C., Rane N. Expert Opin. Investig. Drugs. 10:2001;2105.
2. Prendergast G.C. Curr. Opin. Cell Biol. 12:2000;166.
3. Lobell R.B., Omer C.A., Abrams M.T., Bhimnathwala H.G., Brucker M.J., Buser C.A., Davide J.P., deSolms S.J., Dinsmore C.J., Ellis-Hutchings M.S., Kral A.M., Liu D., Lumma W.C., Machotka S.V., Rands E., Williams T.M., Graham S.L., Hartman G.D., Oliff A.I., Heimbrook D.C., Kohl N.E. Cancer Res. 61:2001;8758.
4. Wang, W.; Curtin, M. L.; Fakhoury, S. A.; Gwaltney, S. L., II; Hasvold, L. A.; Hutchins, C. W.; Li, Q.; Lin, N.; Nelson, L. T. J.; O'Connor, S. J.; Sham, H. L.; Sullivan, G. M.; Wang, G. T.; Wang, X. World Patent WO 01/81316; Chem Abstr. 2001, 135, 344482.
5. Assay methods described in: Vogt A., Qian Y., Blaskovich M.A., Fossum R.D., Hamilton A.D., Sebti S.M. J. Biol. Chem. 270:1995;660.
6. Pharmacokinetic properties were determined by traditional methods or through multiple dosing studies where three compounds and a reference compound were administered at 1 mg/kg in the appropriate species for a total dose of 4 mg/kg. Plasma concentrations were determined by HPLC-MS.
7. All compounds reported have physical data consistent with the assigned structures.
8. Liu H., Ko S.-B., Josien H., Curran D.P. Tetrahedron Lett. 36:1995;8917.
9. Turner R.M., Lindell S.D., Ley S.V. J. Org. Chem. 56:1991;5739.